BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 26.93 Billion | -40.35 Thousand | 48.38 Thousand | - |
| Cost of Revenue | - | 18.43 Thousand | 18.43 Thousand | 342.81 Thousand | 1.4 Million | 294.93 Thousand |
| Gross Profit | - | -18.43 Thousand | 26.93 Billion | -383.17 Thousand | -1.35 Million | -294.93 Thousand |
| Operating Expenses | 3.24 Million | 9.25 Million | 9.96 Million | 7.95 Million | 9.19 Million | 6.45 Million |
| Selling, General and Administrative Expenses | 2.63 Million | 6.56 Million | 4.53 Million | 7.55 Million | 7.74 Million | 5.12 Million |
| Research and Development Expenses | 570.94 Thousand | 2.67 Million | 5.42 Million | 284.7 Thousand | 63.76 Thousand | 430.45 Thousand |
| Other Expenses | 30.35 Thousand | 18.43 Thousand | 18.43 Thousand | 110.71 Thousand | 1.39 Million | -35.14 Thousand |
| Cost and Expenses | 3.24 Million | 9.25 Million | 9.96 Million | 7.95 Million | 9.19 Million | 6.45 Million |
| Operating Income | -3.24 Million | -9.46 Million | -10.2 Million | -7.91 Million | -18.73 Million | -6.84 Million |
| Interest Expense | 50.89 Thousand | 67.17 Thousand | 58.34 Thousand | 40.1 Thousand | 428.77 Thousand | 902 Thousand |
| Income Tax Expense | - | -314.19 Thousand | 166.66 Thousand | -258.00 | 477.16 Thousand | -1.4 Million |
| Earnings before Tax | -2.89 Million | -9.37 Million | -11.99 Million | -36.35 Million | -19.58 Million | -9.14 Million |
| Net Income | -2.88 Million | -9.05 Million | -12.15 Million | -36.35 Million | -20.06 Million | -9.14 Million |
| Earnings Per Share Basic | -0.03 | -0.10 | -0.16 | -1.34 | -1.33 | -1.01 |
| Earnings Per Share Diluted | -0.03 | -0.10 | -0.16 | -1.34 | -1.33 | -1.01 |
| Weighted Average Shares Outstanding | 109.28 Million | 86.56 Million | 75.46 Million | 27.02 Million | 15.03 Million | 9.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 109.28 Million | 86.56 Million | 75.46 Million | 27.02 Million | 15.03 Million | 9.02 Million |
| Gross Margin | - | - | 1.00 | 9.49 | -28.10 | - |
| EBIT Margin | - | - | -0.00 | 194.11 | -159.93 | - |
| Profit Margin | - | - | -0.00 | 900.70 | -414.74 | - |
| EBITDA | -3.19 Million | -9.23 Million | -9.95 Million | -7.79 Million | -7.73 Million | -5.58 Million |
| Earnings Before Tax Margin | - | - | -0.00 | 196.13 | -387.15 | - |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | 18.43 Thousand |
| Gross Profit | - | - | - | - | - | -18.43 Thousand |
| Operating Expenses | 730.24 Thousand | 3.2 Million | 698.62 Thousand | 1.01 Million | 766.44 Thousand | 9.25 Million |
| Selling, General and Administrative Expenses | 544.24 Thousand | - | 565.11 Thousand | 829.77 Thousand | 699.8 Thousand | - |
| Research and Development Expenses | 185.99 Thousand | - | 133.5 Thousand | 184.79 Thousand | 66.64 Thousand | - |
| Other Expenses | -590.55 Thousand | - | 542.03 Thousand | -78.76 Thousand | 92.6 Thousand | 18.43 Thousand |
| Cost and Expenses | 730.24 Thousand | 3.2 Million | 698.62 Thousand | 1.01 Million | 766.44 Thousand | 9.25 Million |
| Operating Income | -730.25 Thousand | -3.2 Million | -856.47 Thousand | -926.97 Thousand | -836.9 Thousand | -9.46 Million |
| Interest Expense | 36.35 Thousand | 50.89 Thousand | 7016.00 | 5872.00 | 1656.00 | 67.17 Thousand |
| Income Tax Expense | 609.04 Thousand | -9478.00 | -169.11 Thousand | 85.15 Thousand | 125.1 Thousand | -314.19 Thousand |
| Earnings before Tax | -693.48 Thousand | -2.89 Million | -213.73 Thousand | -1.02 Million | -963.66 Thousand | -9.37 Million |
| Net Income | -1.3 Million | -2.88 Million | -195.45 Thousand | -1.01 Million | -1.08 Million | -9.05 Million |
| Earnings Per Share Basic | -0.01 | - | -0.00 | -0.01 | -0.01 | - |
| Earnings Per Share Diluted | -0.01 | - | -0.00 | -0.01 | -0.01 | - |
| Weighted Average Shares Outstanding | 115.82 Million | 109.28 Million | 112.84 Million | 109.19 Million | 100 Million | 86.56 Million |
| Weighted Average Shares Outstanding (Diluted) | 115.82 Million | 109.28 Million | 112.84 Million | 109.19 Million | 100 Million | 86.56 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -730.25 Thousand | - | -156.58 Thousand | -1.09 Million | -673.84 Thousand | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
AUROPHARMA
GSTC
NCL
TW
IGLD-M
3648